co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1430 in its research report dated January 29, 2026.
Looking ahead, volatility is expected to pick up sharply over the next 2–3 sessions, with the Union Budget 2026 scheduled to be presented by the Finance Minister on February 1.
Consolidation is expected to continue in the market for the next few sessions. Below are some short-term trading ideas to consider.
Stocks to Watch, 2 January: Stocks like Punjab & Sind Bank, South Indian Bank, Indian Bank, Hyundai Motor India, Hero MotoCorp, TVS Motor, RailTel Corporation of India, Aurobindo Pharma, Time Technoplast, Vodafone Idea, and Multi Commodity Exchange of India will be in focus on January 2.
The market may attempt a bounce back after a four-day losing streak, but sustainability will be key to watch. Below are some short-term trading ideas to consider.
Stocks to Watch, 15 December: Stocks like Wipro, Dr Reddy's Laboratories, SMS Pharmaceuticals, Aurobindo Pharma, ESAF Small Finance Bank, NLC India, Ashoka Buildcon, KEC International, Bharat Electronics, Astra Microwave Products, One 97 Communications Paytm, Refex Industries, and Brigade Enterprises will be in focus on December 15.
Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1430 in its research report dated December 03, 2025.
The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, CFO S Subramanian said
The market is expected to remain rangebound until it decisively surpasses the previous day’s high. Below are some short-term trading ideas to consider.
Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated November 06, 2025.
The market is likely to stay in positive terrain with improving sentiment. Below are some short-term trading ideas to consider.
ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated November 07, 2025.
The consolidation amid range-bound trading may continue in the upcoming sessions due to a lack of triggers. Below are some short-term trading ideas to consider.
The market is expected to consolidate further until a decisive breakout above the previous day's high occurs. Below are some short-term trading ideas to consider.
A report said last month that Aurobindo Pharma was leading the race to buy Zentiva for up to $5.5 billion
Aurobindo Pharma Share Price |
Stocks to Watch, 08 Sept: Stocks like Adani Power, SpiceJet, Jaiprakash Associates, Zydus Lifesciences, Aurobindo Pharma, BHEL, HFCL, Ceigall India, ACME Solar Holdings, Prime Focus, Time Technoplast, Exxaro Tiles, and NTPC Green Energy will be in focus on September 08.
Stocks to Watch, 01 September: Stocks like Torrent Power, NCC, PG Electroplast, BHEL, Popular Vehicles, EPACK Durable, Dharan Infra, Adani Power, Aurobindo Pharma, Classic Electrodes (India), Anondita Medicare, and Shivashrit Foods will be in focus on 01 September.
Aurobindo Pharma said it 'regularly explores' various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value.
Aurobindo Pharma share price: Reports suggested it has emerged as the frontrunner to acquire Prague-based Zentiva for $5 to $5.5 billion. If completed, this would be the largest-ever acquisition by an Indian pharma company.
ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated August 06, 2025.
Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated August 05, 2025.
